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Although telmisartan, an angiotensin II receptor blocker (ARB), has an agonistic action for proliferator-
activated receptor (PPAR)-g in vitro, it remains to be determined whether telmisartan exerts such an
action in vivo using a non-toxic dose (<5 mg/kg in rats). To address the issue, telmisartan (2 mg/kg) and
olmesartan (2 mg/kg), another ARB without PPAR-g agonistic action, were given to spontaneously hy-
pertensive rats (SHR) fed a high fat diet (HFD). HFD decreased plasma adiponectin, and caused insulin
resistance, hypertriglyceridemia and renal damage, which were improved by ARBs. Protective effects of
telmisartan and olmesartan did not signiﬁcantly differ. In addition, in vitro study showed that 1 mM of
telmisartan did not elevate the mRNA expression of adipose protein 2, which is a PPAR-g-stimulated
adipogenic marker gene, in preadipocytes with 3% albumin. To obtain 1 mM of plasma concentration, oral
dose of telmisartan was calculated to be 6 mg/kg, which indicates that PPAR-g agonistic action is
negligible with a non-toxic dose of telmisartan (<5 mg/kg) in rats. This study showed that 2 mg/kg of
telmisartan and olmesartan ameliorated insulin resistance, hypertriglyceridemia and renal damage in
SHR fed a HFD. As beneﬁcial effects of telmisartan and olmesartan did not signiﬁcantly differ, these were
mediated through the PPAR-g-independent actions.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hypertensive patients with insulin resistance and hyperlipid-
emia, which is known as the metabolic syndrome, have the
increased risk of renal and cardiovascular diseases (1). Angiotensin
II type1 (AT1) receptor blocker (ARB) and angiotensin-converting
enzyme inhibitor are reported to improve insulin resistance and
delay the onset of diabetes in hypertensive patients (2).
Peroxisome proliferator-activated receptor (PPAR)-g, a nuclear
receptor mainly expressed in adipocytes, is involved in the regu-
lation of glucose and lipid metabolism (3). Ligands of PPAR-g
improve the insulin sensitivity by a modulation of various gene
expressions such as adiponectin (4,5). Telmisartan, an ARB, directly
binds to the ligand-binding domain of PPAR-g and can act as a
PPAR-g agonist (6). Therefore, it is anticipated that telmisartan: þ81 285 44 7562.
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d/4.0/).provides a greater beneﬁcial effect on glucose and lipid metabolism
and consequently, a better protective effect against organ damages
than other ARBs without PPAR-g activating action do in hyperten-
sive patients with the metabolic syndrome. Compatible with the
idea, telmisartan (10 mg/kg) is reported to have a better renal
protective effect than valsartan (10mg/kg), another ARB, in a model
of metabolic syndrome in rats (7). However, the maximal non-toxic
dose of telmisartan is 5 mg/kg during a repeated dosing in rats (8),
which indicates that 10 mg/kg of telmisartan had exerted a dele-
terious effect and modiﬁed pharmacologic proﬁles. Therefore,
further studies using a non-toxic dose are needed to determine the
protective effect of telmisartan against organ damages in rats with
metabolic syndrome.
Olmesartan, an ARB, is widely used for the treatment of hyper-
tension. Different from telmisartan, in vitro studies showed that
olmesartan did not enhance PPAR-g-mediated transcript activity
(9), although the drug improved insulin sensitivity (10). In this
study using a non-toxic dose, the protective effects of telmisartan
against the insulin resistance, hypertriglyceridemia and renal
damage were compared with those of olmesartan in spontaneouslynese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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be one of animal models of metabolic syndrome (7).
2. Materials and methods
1) In vivo study
2.1. Animals
Animal experiments were carried out in a humane manner after
receiving approval from the Institutional Animal Experiment
Committee of Jichi Medical University (13e216, 14e114, Tochigi,
Japan), according to the National Institutes of Health Guidelines for
the Care and Use of Laboratory Animals. Animals were housed
under a 12:12 h light/dark cycle at a room temperature of 24 ± 1 C
and humidity of 60 ± 10%. All animals were exposed to the light/
dark cycle for at least 7 days before the experiment.
2.2. Study protocol
2.2.1. Experiment 1
Seven week-old male spontaneously hypertensive rats (SHR)
were purchased from Japan SLC (Shizuoka, Japan). SHR were
divided into ﬁve groups and fed a high fat diet (HFD) (D12492,
60% kcal as fat, Research Diets, New Brunswick, NJ) ad libitum. SHR
were treated with vehicle (1% tragacanth gum solution), telmi-
sartan (1 mg/kg), telmisartan (2 mg/kg), olmesartan (1 mg/kg) or
olmesartan (2 mg/kg) once daily by gastric gavage. After more than
4 weeks-treatment, mean arterial blood pressure was measured for
24 h under a conscious state.
2.2.2. Experiment 2
Sevenweek-old male SHRwere divided into four groups and fed
either control fat diet (D12450J, 7% kcal as fat, Research Diets) or
HFD. Groups 1 received control fat diet (control diet) and were
treated with vehicle. Groups 2e4 received HFD and was orally
treated with vehicle (HFD-vehicle), 2 mg/kg telmisartan (HFD-Tel)
or 2 mg/kg olmesartan (HFD-Olm) once daily for 11 weeks. Systolic
blood pressure was also measured in all groups at every 5 weeks
using a standard tail-cuff sphygmomanometer (KN-201, Natsume,
Tokyo, Japan) in an awake state throughout the experimental
period. Insulin tolerance test was performed on week 9. Urine
samplewas collected for 24 h in a metabolic cage onweek 11. At the
end of the study, animals were anesthetized with pentobarbital
sodium (50 mg/kg i.p.), and blood and kidney samples were
collected after fasting for 12 h.
2.3. Mean arterial blood pressure measurement
Rats were anesthetized with pentobarbital sodium (50 mg/kg
i.p.) and a polyethylene catheter (PE-50; Becton Dickinson, Franklin
Lakes, NJ) ﬁlled with heparinized saline (10 U/ml, 0.05 ml/min) was
inserted into the left common carotid artery and connected to a
pressure transducer (P-3000S; Nidec Copal Electronics Co., Tokyo,
Japan). Mean arterial blood pressure was recorded continuously in
the animals under an alert and unrestrained condition, and with
free access to food and water. Recording started more than 12 h
after the surgery.
2.4. Insulin tolerance test
Rats were intraperitoneally injected with 0.75 U/kg of regular
insulin without fasting. Blood was collected from the tail vein
before and at 15, 30, 60 and 90 min after the injection.2.5. Assays
Blood glucose concentrationwasmeasured using a Glutest Ace R
(Sanwa Kagaku Kenkyusyo, Nagoya, Japan). Serum insulin and
adiponectin concentrations were measured using commercialized
enzyme-linked immunosorbent assay kits (Mercodia AB, Uppsala,
Sweden; and R&D systems, Minneapolis, MN). The following for-
mula was used to calculate the homeostasis model assessment for
insulin resistance (HOMA-IR): [fasting insulin (mU/mL)  fasting
glucose (mg/dl)]/405. Urinary albumin was measured by immu-
nonephelometry. Urinary monocyte chemoattractant protein-1
(MCP-1) and 8-hydroxy-20-deoxyguanosine (8-OHdG) concentra-
tions were measured using enzyme immuno assay kits (IBL,
Fujioka, Japan; and JalCA, Shizuoka, Japan). Triglyceride concen-
trations in serumwere measured by triglyceride E-test kit based on
glycerol-3-phosphate oxidase-DAOS method (Wako Pure Chemical
Industries, Osaka, Japan).
2.6. Histopathological renal examination
Formalin ﬁxed kidney sections were embedded in parafﬁn, cut
into 5 mm thick sections and then stained with Periodic acid-Schiff
staining for histopathological analysis. Samples were examined
for glomerular injury by one of authors (YA) blinded to the
treatment protocol of the animals. At least 50 glomeruli in each
sample were graded from 0 to 4 according to the severity of the
glomerular sclerosis: 0 ¼ normal, 1 ¼ slight glomerular damage,
the mesangial matrix and/or hyalinosis with focal adhesion,
involving sclerosis of <25% of the glomerulus, 2 ¼ sclerosis of
25e50%, 3 ¼ sclerosis of 50e75%, and 4 ¼ sclerosis of >75% of the
glomerulus.
2) In vitro study
2.7. Cells
3T3-L1 cells, the mouse preadipocyte, were maintained in
DMEM supplemented with 10% fetal bovine serum (FBS, Thermo
Fisher Scientiﬁc) and antibiotics (100 U/ml penicillin and 100 mg/ml
streptomycin, Thermo Fisher Scientiﬁc) at 37 C in a humidiﬁed 5%
CO2 atmosphere.
2.8. Adipocyte differentiation
For an induction of adipose differentiation, 3T3-L1 cells were
seeded at 1.5  105 cells per well in 6-well culture plates and then
were grown to conﬂuence. Brieﬂy, differentiation was induced by
treating with 0.25 mM dexamethasone, 500 mM isobutyl methyl-
xanthine and 1 mg/ml insulin in DMEM/FBS on day0. On day3, the
medium was replaced with terminal differentiation medium
(1 mg/ml insulin in DMEM/FBS). On day6, the medium was
replaced with DMEM/FBS, and cells were fed for 2 days until as-
says (day 8).
i) Cells were exposed to 3.0% albumin and telmisartan (1, 10 or
100 mM).
ii) Cells were treated with telmisartan (10 mM) or olmesartan
(10 mM).
Drugs were added continuously into culture media from the
initiation of differentiation to the end of sample collection. In this
study, PPAR-g activity was evaluated by the mRNA expressions of
adipose protein 2 (aP2) and adiponectine, adipogenic marker genes
(11).
Fig. 1. Effects of telmisartan (Tel) (A) and olmesartan (Olm) (B) after dosing for more
than 4 weeks on mean arterial blood pressure (MAP) in SHR fed a high fat diet (HFD).
Mean ± SD, n ¼ 3e4.
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Total RNA from cells was extracted using the RNeasy Mini Kit
(QIAGEN, Valencia, CA), following the manufacturer's instructions,
and was used for the preparation of cDNA using the PrimeScript RT
reagent Kit (Takara Bio, Shiga, Japan). The quantiﬁcation of gene
expression level was performed by a real-time PCR using SYBR®
Premix TaqII (Takara Bio). Speciﬁc primers for each gene were
shown in Supplemental Table 1. Gene expression levels were
normalized to Ribosomal protein S18 and were analyzed using the
comparative threshold cycle method.
2.10. Calculation of a required dose of telmisartan
The present in vitro study with 3.0% albumin showed that PPAR-
g agonistic activity was not detected by 1 mM (515 ng/ml) of tel-
misartan, but by 10 mM (5150 ng/ml) of the drug. Assuming the
pharmacokinetics of telmisartan can be described by the 1-
compartment model, required dose (D) of telmisartan (mg/kg) to
obtain 515 (or 5150) ng/ml of maximum concentration (Cmax) was
calculated using follows equations (1) and (2).













ka; absorption constant, ke; elimination constant.
The following pharmacokinetic data about telmisartan are re-
ported in rats: time to maximum concentration (tmax), 2 h;
bioavailability (F), 66%; distribution of volume (Vd), 5.3 l/kg; and
apparent clearance (Cl/f), 27 ml/min/kg (12).
2.11. Statistical analysis
Data are expressed as the mean ± SD. The repeated-measured
ANOVA was used for the temporal data. Groups were compared
by one-way ANOVA, and the difference between the two groups
was analyzed by the BonferronieDunn test. The p < 0.05 was
considered to be signiﬁcant.
3. Results
3.1. Effects of telmisartan and olmesartan on blood pressure
Repeated dosing of telmisartan (Fig.1A) and olmesartan (Fig.1B)
dose-dependently decreasedmean arterial blood pressure (MAP) in
SHR. Differences in the area under the MAP-time course (AUC,
mmHg hr) between the vehicle- and drug-groups were as follows;
telmisartan 1 mg/kg: 708 ± 93, telmisartan 2 mg/kg: 1282 ± 175,
olmesartan 1 mg/kg: 596 ± 62 and olmesartan 2 mg/kg:
1393 ± 230. As there were no signiﬁcant differences in the AUC
between telmisartan-1 mg/kg and olmesartan-1 mg/kg groups, or
telmisartan-2 mg/kg and olmesartan-2 mg/kg groups, telmisartan
2 mg/kg and olmesartan 2 mg/kg were selected in the further
experiments.
3.2. Effects of telmisartan and olmesartan on body weight, food
intake and blood pressure
Compared to SHR with control diet, body weight was slightly,
but not signiﬁcantly increased in rats with a high fat diet alone
(Fig. 2A). Telmisartan or olmesartan did not signiﬁcantly inﬂuencebody weight and food intake during 10 weeks (Fig. 2A,B). These
drugs similarly decreased blood pressure in SHR (Fig. 2C).
3.3. Effects of telmisartan and olmesartan on glucose and lipid
metabolism
After the injection of insulin, the decrease in blood glucose in
rats with vehicle was signiﬁcantly smaller than that in animals with
control diet (Fig. 3A). However, there were no signiﬁcant differ-
ences in the variable between the control and drug-treated groups.
Fig. 2. Effects of telmisartan (HFD-Tel) and olmesartan (HFD-Olm) for 10 weeks on body weight (BW) change (A), food intake (B) and blood pressure (BP) (C) in SHR fed a high fat
diet (HFD). **p < 0.01 vs. control diet, ##p < 0.01 vs. HFD-vehicle, Mean ± SD, n ¼ 6.
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had signiﬁcantly lowerplasmaadiponectin concentration,whichwas
similarly ameliorated by telmisartan and olmesartan (Fig. 3B).
At the end of the study, the values of HOMA-IR and plasma
triglyceride concentration were signiﬁcantly higher in the vehicle
group, which were similarly corrected by telmisartan and olme-
sartan (Table 1).
3.4. Effects of telmisartan and olmesartan on urinary albumin and
renal histopathology
Compared to the groups with control diet and vehicle alone,
urinary albumin excretion signiﬁcantly reduced in the groups with
the drugs (Fig. 4A). High fat diet increased the urinaryMCP-1 and 8-
OHdG excretions (Fig. 4B,C), and caused glomerular injury, which
were ameliorated by the drugs (Fig. 5, Table 2). Effects of telmisartan
and olmesartan on these variables did not signiﬁcantly differ.
3.5. Effect of telmisartan on mRNA expressions in 3T3-L1
adipocytes
Telmisartan concentration-dependently elevated the aP2 and
adiponectin mRNA expressions in the adipocytes with 3.0%albumin (Fig. 6). Although 1 mM (515 ng/ml) of telmisartan at 3.0%
albumin did not signiﬁcantly elevated aP2 mRNA expression, the
stimulating effect was detected at 10 mM (5150 ng/ml) of the drug.
Under the conditionwith 3.0% albumin, only 100 mM of telmisartan
signiﬁcantly increased adiponectinmRNA expression. To obtain 515
and 5150 ng/ml of Cmax, oral doses of telmisartanwere calculated to
be 6 and 60 mg/kg, respectively.
Under the condition without additional albumin, 10 mM of tel-
misartan signiﬁcantly elevated the aP2 and adiponectin mRNA
expressions in the adipocytes, but olmesartan (10 mM) did not exert
such stimulating effects (Fig. 7).
4. Discussion
To compare a blood pressure-unrelated effect of antihyperten-
sive drugs, it is essential for selecting a dose of drug to obtain an
identical blood pressure-lowering action. In this study, blood
pressure-lowering effects of 2 mg/kg of telmisartan and 2 mg/kg of
olmesartan did not signiﬁcantly differ during the repeated dosing,
and, therefore, 2 mg/kg/day of each drug was used in further
studies.
As a maximal non-toxic dose of telmisartan is reported to be
5 mg/kg during a repeated dosing in rats (8), it is expected that
Fig. 3. Effects of telmisartan (HFD-Tel) and olmesartan (HFD-Olm) for 9 weeks on
insulin tolerance test (ITT) (A) and for 11 weeks on serum adiponectin concentration
(B) in SHR fed a high fat diet (HFD). *p < 0.05, **p < 0.01 vs. control diet (CD), #p < 0.05
vs. HFD-vehicle, Mean ± SD, n ¼ 6.
Table 1
Effects of telmisartan and olmesartan for 11 weeks on fasting blood glucose, insulin
and triglyceride in SHR fed a high fat diet.




63.2 ± 5.4 77.6 ± 8.0 76.8 ± 3.4 74.0 ± 11.0
Insulin (ng/ml) 0.10 ± 0.01 0.32 ± 0.25 0.12 ± 0.05 0.16 ± 0.10
HOMA-IR 0.41 ± 0.04 1.52 ± 1.07* 0.63 ± 0.21 0.71 ± 0.33
Triglyceride (mg/dl) 21.1 ± 6.6 52.6 ± 30.7* 35.9 ± 9.0 31.1 ± 7.1
*p < 0.05 vs control diet, Mean ± SD, n ¼ 6.
Fig. 4. Effects of telmisartan (HFD-Tel) and olmesartan (HFD-Olm) for 11 weeks on
urinary excretions of albumin (A), MCP-1 (B) and 8-OHdG (C) in SHR fed a high fat diet
(HFD). *p < 0.05, **p < 0.01 vs. control diet (CD), #p < 0.05, ##p < 0.01 vs. HFD-vehicle,
Mean ± SD, n ¼ 6.
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Fig. 5. Representative images of Periodic acid-Schiff staining. Scale bar: 100 mm.
Table 2
Effect of telmisartan and olmesartan for 11 weeks on renal damage in SHR fed a high
fat diet.




0.88 ± 0.28 1.69 ± 0.15** 1.14 ± 0.21# 1.08 ± 0.24#
**p < 0.01 vs control diet, #p < 0.05 vs HFD-vehicle, Mean ± SD, n ¼ 6.
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study with SHR fed a high fat diet, the increase of body weight and
the amount of food intake did not signiﬁcantly differ between
vehicle group and 2 mg/kg of telmisartan group during the
repeated dosing for 10 weeks under the present condition. On the
other hand, 10 mg/kg of telmisartan was given to SHR fed a high fat
diet for 10 weeks in the previous study (7). At the end of the
experiment, body weight in the telmisartan-treated SHR was
signiﬁcantly lower than that of vehicle-treated rats, which suggests
that 10 mg/kg of telmisartan affects the body weight gain in these
animals.
In this study, telmisartan and olmesartan signiﬁcantly improved
the insulin resistance and hypertriglyceridemia, and ameliorated
renal damage in SHR fed a high fat diet. In addition, such the effects
of telmisartan did not signiﬁcantly differ from those of olmesartan.
Based on the data, it is speculated that the beneﬁcial effects of
telmisartan detected in this study were mediated through the
PPAR-g-independent actions under the present condition.
In this study with 3% albumin, 1 mM of telmisartan did not
elevate the aP2mRNA expression in 3T3-L1 adipocytes while 10 mM
of the drug signiﬁcantly elevated the variable. As PPAR-g activity is
reﬂected in the aP2 mRNA expression (11), these in vitro datasuggest that 1 mM of telmisartan did not exert a PPAR-g agonistic
activity under the condition with 3% albumin. In general, a protein-
unbound drug is involved in the expression of pharmacologic ac-
tion. Our previous in vitro study showed that albumin
concentration-dependently reduced the unbound fraction of tel-
misartan, and 16e26% of the drug was unbound at 3.0% albumin
(submitted). Therefore, the unbound fractions of 1 and 10 mM of
telmisartan at 3.0% albumin are calculated to be 0.16e0.26 mM and
1.6e2.6 mM, respectively. As the 50% effective concentration for
PPAR-g activation is reported to be 1e10 mM (9),1 mMof telmisartan
at 3.0% albumin might be too low to activate PPAR-g. In addition, to
obtain 1 mM (515 ng/ml) of plasma concentration (including un-
bound and bound fractions), oral dose of telmisartanwas calculated
to be 6 mg/kg, which is toxic dose (>5 mg/kg) in rats (8). Therefore,
these data indicate that PPAR-g agonistic action of telmisartan is
negligible during a repeated dosing of a non-toxic dose of the drug
(less than 5 mg/kg) in rats.
High fat diet augments oxidative stress in SHR (13), which, in
turn, might reduce the secretion of adiponectin from adipocytes
(14). These mechanisms can, at least in part, explain the decreased
plasma adiponectin in SHR fed a high fat diet in this study. Adi-
ponectin plays a major role in glucose and lipid metabolism, and
has also anti-inﬂammatory effect (15). The decreased plasma adi-
ponectin seems to be involved in the following ﬁndings in SHR fed a
high fat diet in this study and other studies (7,16); 1) The reduced
insulin sensitivity and increased plasma triglyceride, and 2) The
enhanced renal inﬂammation reﬂected in the elevated urinary
MPC-1, and consequent renal damage.
Angiotensin II decreases plasma adiponectin concentration
through the action on AT1 receptors (17), while ARB increases the
variable (18). In addition, ARB diminishes the aldosterone-
mediated suppression of adiponectin production by adipocytes
Fig. 6. Effects of telmisartan on aP2 (A) and adiponectin (B) mRNA expressions in 3T3-
L1 adipocytes under the condition with 3% albumin. Mean mRNA expression level of
vehicle group was set to 1.0. *p < 0.05, **p < 0.01 vs. vehicle, Mean ± SD, n ¼ 3.
Fig. 7. Effects of telmisartan and olmesartan on aP2 (A) and adiponectin (B) mRNA
expressions in 3T3-L1 adipocytes. Mean mRNA expression level of vehicle group was
set to 1.0. **p < 0.01 vs. vehicle, Mean ± SD, n ¼ 3.
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property, the drug elevated plasma adiponectin concentration in
SHR fed a high fat diet, which is similar to telmisartan. Therefore, a
blockade of AT1 receptor would be involved in the PPAR-g-inde-
pendent pathways for the elevating plasma adiponectin concen-
tration by telmisartan and olmesartan in this study.
In this study, telmisartan and olmesartan similarly elevated
plasma adiponectin concentration in SHR fed a high fat diet, and
the high fat diet-induced changes were improved as follows;
1) Correction of insulin resistance:
Adiponectin activates AMP-activated protein kinase, which in-
hibits hepatic gluconeogenesis and increases muscle glucose
transport (15), and consequently, improves insulin resistance.
2) Decrease in plasma triglyceride concentration:
CD-36 (fatty acid transporter), acyl-coenzyme A and uncoupling
protein-2 are involved in fatty acid transport and oxidation (15).
Adiponectin can stimulate these proteins in muscle and increase fat
combustion and energy waste (15, 20), and consequently, decreases
plasma triglyceride.
3) Amelioration of renal damage:
MCP-1 is involved in the recruitment of monocytes and regu-
lation of migration and inﬁltration of monocytes/macrophages, andit causes inﬂammation and tissue damage (21). Adiponectin de-
creases MCP-1 expression in tissues (22), and consequently, ame-
liorates renal damage. Blood pressure-lowering action of ARBs also
contributed to the renal protective effect of these drugs.
Angiotensin II up-regulates NADPH oxidase which produces
reactive oxygen species (ROS) (23). In addition, it is suggested that
an increased production of ROS contributes to diabetic complica-
tions (24). Previous study showed that ARBs might suppress
NADPH oxidase-mediated ROS production via AT1 receptor (25),
which might be a potential pathway involved in PPAR-g-indepen-
dent pathways. In this study, elevated urinary excretion of 8-OHdG
by a high fat diet, a marker of oxidative DNA damage, was
ameliorated by telmisartan and olmesartan. Based on these ﬁnd-
ings, AT1 receptor blockade-mediated reduction in ROS production
would be involved in the PPAR-g-independent pathways linking to
the beneﬁcial effects of these drugs.
In summary, this study showed that telmisartan and olmesartan
improved insulin resistance, corrected hypertriglyceridemia and
H. Yanagihara et al. / Journal of Pharmacological Sciences 131 (2016) 190e197 197ameliorated renal damage in SHR fed a high fat diet after a repeated
dosing of under the maximal non-toxic dose (<5 mg/kg). As the
beneﬁcial effects of telmisartan did not signiﬁcantly differ from
those of olmesartan, these were mediated through the PPAR-g-in-
dependent actions involving a blockade of AT1 receptor, under the
present condition.
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